AU2018375298A1 - Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis - Google Patents

Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis Download PDF

Info

Publication number
AU2018375298A1
AU2018375298A1 AU2018375298A AU2018375298A AU2018375298A1 AU 2018375298 A1 AU2018375298 A1 AU 2018375298A1 AU 2018375298 A AU2018375298 A AU 2018375298A AU 2018375298 A AU2018375298 A AU 2018375298A AU 2018375298 A1 AU2018375298 A1 AU 2018375298A1
Authority
AU
Australia
Prior art keywords
pirfenidone
administered
ubenimex
nash
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018375298A
Other languages
English (en)
Inventor
David Cory
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eiger Biopharmaceuticals Inc
Original Assignee
Eiger Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals Inc filed Critical Eiger Biopharmaceuticals Inc
Publication of AU2018375298A1 publication Critical patent/AU2018375298A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018375298A 2017-11-28 2018-11-27 Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis Abandoned AU2018375298A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762591667P 2017-11-28 2017-11-28
US62/591,667 2017-11-28
PCT/US2018/062645 WO2019108551A1 (en) 2017-11-28 2018-11-27 Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
AU2018375298A1 true AU2018375298A1 (en) 2020-05-28

Family

ID=66664242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018375298A Abandoned AU2018375298A1 (en) 2017-11-28 2018-11-27 Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Country Status (7)

Country Link
US (1) US20210369693A1 (cg-RX-API-DMAC7.html)
EP (1) EP3716975A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021504479A (cg-RX-API-DMAC7.html)
CN (1) CN111386115A (cg-RX-API-DMAC7.html)
AU (1) AU2018375298A1 (cg-RX-API-DMAC7.html)
CA (1) CA3082178A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019108551A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1031925B1 (de) * 2024-06-03 2025-10-30 Univ Guizhou Medical Eine orale, leberzielgerichtete nanoemulsion zur beladung mit pirfenidon sowie deren herstellungsverfahren und anwendung

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102399254B1 (ko) 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
KR20240009415A (ko) * 2021-04-19 2024-01-22 카탈리스트 바이오사이언시즈, 인코포레이티드 질환에 대한 약학적 하이드로니돈 제형
WO2023220003A1 (en) * 2022-05-10 2023-11-16 Opko Pharmaceuticals, Llc Topical ophthalmic pirfenidone-loaded liposomes to increase the therapeutic activity of the drug in cornea and useful for prevention or therapy of corneal haze

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1098249C (zh) * 1995-06-21 2003-01-08 国家医药管理局四川抗菌素工业研究所 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途
AU2001230605A1 (en) * 2000-02-09 2001-08-20 Shionogi And Co., Ltd. Apoptosis inhibitor
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
WO2013142369A1 (en) * 2012-03-23 2013-09-26 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pulmonary hypertension with leukotriene inhibitors
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
MX2018005096A (es) * 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
WO2017108744A1 (de) * 2015-12-22 2017-06-29 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
KR102399254B1 (ko) * 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
MX364040B (es) * 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1031925B1 (de) * 2024-06-03 2025-10-30 Univ Guizhou Medical Eine orale, leberzielgerichtete nanoemulsion zur beladung mit pirfenidon sowie deren herstellungsverfahren und anwendung

Also Published As

Publication number Publication date
EP3716975A1 (en) 2020-10-07
WO2019108551A1 (en) 2019-06-06
EP3716975A4 (en) 2022-01-12
CA3082178A1 (en) 2019-06-06
US20210369693A1 (en) 2021-12-02
JP2021504479A (ja) 2021-02-15
CN111386115A (zh) 2020-07-07

Similar Documents

Publication Publication Date Title
Gawrieh et al. Saroglitazar, a PPAR‐α/γ agonist, for treatment of NAFLD: a randomized controlled double‐blind phase 2 trial
US11571403B2 (en) Methods for the treatment of non-alcoholic steatohepatitis
AU2013259526B2 (en) New methods
US10441560B2 (en) Compositions and methods for treating non-alcoholic steatohepatitis
JP6865038B2 (ja) Nafldおよびnashの治療
AU2014353246A1 (en) Treatment of homozygous familial hypercholesterolemia
WO2019108551A1 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
US20230181602A1 (en) Treatment of non-alcoholic steatohepatitis (nash)
CN111093705A (zh) 包含fxr激动剂的组合
JP2019530696A (ja) 線維性、硬変性の疾患もしくは障害を治療または予防するためのfxrアゴニストを含む組合せ組成物
US20230181601A1 (en) Treatment of non-alcoholic steatohepatitis (nash)
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
WO2019099509A1 (en) Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder
JP2022548617A (ja) Fxrアゴニストを含む処置
TW202214256A (zh) 非酒精性脂肪肝炎(nash)之治療
HK40089967A (en) Treatment of non-alcoholic steatohepatitis (nash)
HK40089720A (en) Treatment of non-alcoholic steatohepatitis (nash)

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period